Hiv Infection Articles & Analysis
32 news found
Despite progress, an effective animal model that mimics human immune response during HIV/TB co-infection has been lacking, hindering treatment and vaccine development. Bohorguez et al. (2024) developed a humanized NSG-SGM3 mouse model to advance HIV/TB co-infection studies. These mice are transplanted with human CD34+ stem ...
In addition, these new reagents can be applied in various fields, such as mRNA-base vaccine therapy for malignant tumors, protein replacement therapy, and gene editing using mRNA recombination technology. mRNA vaccines protect against infectious diseases like influenza, rabies, HIV and Zika virus infections. This mRNA Transfection Reagent (Catalog: WHM-OB24, unit ...
The completion of the facility will accelerate patient access to the new drug, and improve the prevention and and treatment of HIV infection in the region. Hao Yang encouraged the company to fulfill its social responsibilities, continue to actively participate in and support the AIDS prevention and control work, develop more innovative drugs, and contribute to ...
Nowadays human papillomavirus (HPV) infection has been recognized as the prerequisite for most anogenital malignancies accounting for more than 90% of cervical and anal cancers, thus making it necessary to implement screening for anal cancer prevention in HIV-infected population. ...
Frontier Biotechnologies announced that the Azerbaijan Republic Ministry of Health approved Aikening® (Albuvirtide), the first long-acting intravenous infusion for the treatment of HIV-1 infection in adults. Aikening® is a new fusion inhibitor given once weekly, used in combination dual therapy to treat people living with HIV who have ...
Continued the recruitment for two Phase 2 clinical trials of BIT225 for treatment of HIV-1 infection at sites in Australia and Thailand. Continued the design, synthesis and testing of new compounds under its HIV-1 program, with the aim of identifying a next generation lead anti-HIV-1 drug. ...
We have decided to donate to the Diocesan Missionary Center of Padua in favor of the Bukumbi Hospital in Tanzania. In Tanzania, HIV infection affects on average 4% of the population. The hospital has a therapy and treatment center for AIDS patients and the Diocesan Missionary Center of Padua is committed to the prevention and treatment of about one hundred ...
"This partnership with Orion aims to develop a first-of-its-kind product with potential to revolutionize the way women protect their sexual and reproductive health: no unintended pregnancies, no STIs, and no HIV -- all in one applicator." Ian McGowan, Chief Medical Officer of Orion Biotechnology, added, "It is unacceptable that we are still seeing high rates of new ...
It is considered to be a regulator of the latent process of the human immunodeficiency virus (HIV) infection. In addition to pseudoUridine, pseudoUridine derivatives such as 1-methylpseudoUridine, 3-methylpseudoUridine, 2'-O-methylpseudoUridine and ultramodified residue 1 -Methyl-3-(3-amino-3-carboxypropyl) pseudoUridine are also popular products of BOC Sciences. ...
A positive test allows individuals to then seek treatment (there are several forms of effective treatment currently available) and prevent transmission to others. How HIV Testing Works There are a variety of different HIV tests available, and while all these tests are very accurate, none can detect the virus immediately after infection (due to ...
ByFluxergy
Overall, the product had a positive acceptability profile, and when questioned, the majority of study participants stated that they would use the product for protection against HIV or pregnancy if the gel was subsequently licensed for these indications. ...
Gries has had exposure over a broad range of disease areas: oncology, inflammation and pain, the central nervous system, metabolism, cardio-renal syndrome, anti-infectives (including HIV and HCV), dermatology, ophthalmology, genito-urinary and gastroenterology. ...
OB-002, a highly potent chemokine analog of CCL5 (a ligand for the CCR5 HIV co-receptor), has previously been shown to be completely protective in a non-human primate model of vaginal HIV transmission (Veazey R et al. ...
Massari has led teams that have registered treatments for rare diseases as well as ground-breaking therapies for resistant bacterial infections and HIV. He has built and led teams in North America, South America, Europe and Japan. ...
BV is one of the most frequent vaginal infections and affects approximately 30% of reproductive-aged women in the U.S. ...
Orion plans to submit the study data to the HIVR4P HIV prevention meeting which will be held in Cape Town South Africa in January 2021 (https://www.hivr4p.org/). ...
Current TB diagnostics on the market have difficulty distinguishing latent (i.e. asymptomatic and nonprogressive) TB infections from active TB disease and detecting active TB across the full spectrum of affected patient groups. Unlike currently available methods, however, NanoPin’s TB test demonstrates robust diagnostic performance for pulmonary and extrapulmonary, ...
Tenofovir is one of the most frequently used antiretroviral drugs in the multi-drug treatment of HIV infection. However, since tenofovir does not cross the BBB following systemic administration, the treatment is not effective against viral reservoirs in the central nervous system (CNS). The persistence of HIV in the CNS (called ...
The panel will consider the mixed success of the eight MDGs, which were set in 2000 and provide targets for reducing poverty and promoting social development through such areas as education, reduction of HIV infection rates and infant mortality. "In the years since the MDGs were agreed, we have made significant progress and learned many lessons on how to reduce ...
Until 2000, Streptococcus pneumoniae infections caused 100,000-135,000 hospitalizations for pneumonia, 6 million cases of ear infections, and 60,000 cases of invasive disease, including 3300 cases of meningitis. ...